好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Demographic and Subsequent Funding Trends in the AAN Research Program (1996-2021)
Practice, Policy, and Ethics
P17 - Poster Session 17 (11:45 AM-12:45 PM)
1-002
To assess demographic and subsequent funding trends over the 25-year duration of the 好色先生 (AAN) Research Program.
A greater proportion of successful underrepresented in Medicine (UIM) neuroscientists could help address disparities in neurological outcomes, bolster minority participation in research, and mentor diverse early career individuals. However, National Institutes of Health (NIH) data indicate that UIM scientists lack significant federal funding. The AAN Research Program supports different types of research across career stages and can be a funding momentum booster for early career investigators. 
We obtained a list of the online publicly accessible AAN Research Program awardees and obtained their contact information from the AAN Online Directory. Emails were sent to all prior awardees inquiring about their self-reported gender, race, and prior acquisition of NIH grants post-AAN funding. If a response was not obtained after 2 attempts, the awardee’s name was inserted into an online search engine (Google) to determine if their self-identified race was publicly available or if their phenotype and/or name appeared to fall into a particular racial category. Descriptive statistics and analysis of proportions were used for data analysis.

Since the inception of the AAN Research Program, 272 individuals were funded (information available: 271), going from 1 award in 1996 to 15 awards in 2021. Overall, 41.3% were women, 3.7% were Black, and 4.8% were Hispanic/Latino. Over 25 years, there was no significant change in the proportion of grants received by gender or racial group. 50.5% received at least one NIH grant after AAN funding (38% career development, 23.2% independent research), of which, 39.4% were women, 2.2% were Black, and 4.4% were Hispanic/Latino.

The AAN Research Program has grown substantially over the last quarter century.  Greater efforts might be warranted to bolster the numbers of UIM recipients and their ability to obtain subsequent federal funding.
Authors/Disclosures
Daniela A. Pimentel Maldonado, MD, MSCR (U.S. Food and Drug Administration)
PRESENTER 		Dr. Pimentel Maldonado has nothing to disclose.
Tachira Tavarez, MD Dr. Tavarez has nothing to disclose.
Alejandro Vargas, MD, MS, FAAN (Rush University Medical Center) Dr. Vargas has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer U.S. LLC Pharmaceuticals.
Gabriel M. Moreno, MD Dr. Moreno has nothing to disclose.
Raelle Tagge Raelle Tagge has nothing to disclose.
Daniel T. Lackland, PhD (Medical University of South Carolina) An immediate family member of Prof. Lackland has received personal compensation for serving as an employee of Sound Pharmacetical. Prof. Lackland has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley Publishing. Prof. Lackland has received publishing royalties from a publication relating to health care.
Bruce I. Ovbiagele, MD, MSc, FAAN (San Francisco VA) Dr. Ovbiagele has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Stroke Association. Dr. Ovbiagele has received research support from National Institutes of Health. Dr. Ovbiagele has a non-compensated relationship as a President with Society for Equity Neuroscience that is relevant to AAN interests or activities. Dr. Ovbiagele has a non-compensated relationship as a Board Member with World Stroke Organization that is relevant to AAN interests or activities.